Related Experiment Video
Updated: Jun 16, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Pharmacokinetic-pharmacodynamic modelling in a clinical pilot study of rituximab in multiple sclerosis: Towards
Trond Trætteberg Serkland1,2, Silje Skrede1,2, Erik Ingmar Hallin1
1Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.
Aims:
Rituximab (RTX) is used off-label for relapsing-remitting multiple sclerosis, although dosing regimens vary. Observational data suggest the standard 6-month interval may be extended and individualized. We aimed to develop a pharmacokinetic-pharmacodynamic (PKPD) model to describe patient-specific RTX concentrations and CD19+ lymphocyte counts.
Methods:
Thirteen treatment-naïve patients initiated RTX treatment with 1000 mg intravenously. Blood samples were collected at 6 time points during the following 6 months. RTX concentrations and CD19+ lymphocyte counts were used to compare different PKPD using the nonlinear mixed-effects software Monolix.
Results:
Initial pharmacokinetics of RTX could be described by a 1-compartment model with nonlinear target-mediated elimination of rituximab. Introduction of CD19+ lymphocyte counts as a pharmacodynamic marker resulted in comparable performance of a 1-compartment and a 2-compartment model and can provide descriptions of RTX concentrations and CD19+ lymphocyte counts in individual patients. In both models, nonspecific clearance (CL) contributes approximately 10 times more to the overall elimination than target-mediated clearance (kdeg,1; CL [1/day] = 0.075 ± 0.035 [median 0.061], kdeg,1 [mm-3/day] = 0.125 ± 0.311 [median 0.007] and CL [1/day] = 0.036 ± 0.027 [median 0.026], kdeg,1 [mm-3/day] = 0.004 ± 0.002 [median 0.003]).
Conclusions:
The PKPD models were able to describe the data both in patients exhibiting enduring CD19+ lymphocyte depletion and in patients exhibiting signs of early CD19+ lymphocyte repopulation. Additional data are required to validate and advance models for prediction of repopulation dynamics and, eventually, individualized RTX dosing.
More Related Videos
Related Concept Videos
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Analysis of Population Pharmacokinetic Data
One-Compartment Open Model for IV Bolus Administration: General Considerations
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...

